A Risk Model of Gene Signatures for Predicting Platinum Response and Survival in Ovarian Cancer

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2022 Apr 1

PMID 35361267

Authors

Siyu Chen

Yong Wu

Simin Wang

Jiangchun Wu

Xiaohua Wu

Zhong Zheng

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer (OC) is the deadliest tumor in the female reproductive tract. And increased resistance to platinum-based chemotherapy represents the major obstacle in the treatment of OC currently. Robust and accurate gene expression models are crucial tools in distinguishing platinum therapy response and evaluating the prognosis of OC patients.

Methods: In this study, 230 samples from The Cancer Genome Atlas (TCGA) OV dataset were subjected to mRNA expression profiling, single nucleotide polymorphism (SNP), and copy number variation (CNV) analysis comprehensively to screen out the differentially expressed genes (DEGs). An SVM classifier and a prognostic model were constructed using the Random Forest algorithm and LASSO Cox regression model respectively via R. The Gene Expression Omnibus (GEO) database was applied as the validation set.

Results: Forty-eight differentially expressed genes (DEGs) were figured out through integrated analysis of gene expression, single nucleotide polymorphism (SNP), and copy number variation (CNV) data. A 10-gene classifier was constructed which could discriminate platinum-sensitive samples precisely with an AUC of 0.971 in the training set and of 0.926 in the GEO dataset (GSE638855). In addition, 8 optimal genes were further selected to construct the prognostic risk model whose predictions were consistent with the actual survival outcomes in the training cohort (p = 9.613e-05) and validated in GSE638855 (p = 0.04862). PNLDC1, SLC5A1, and SYNM were then identified as hub genes that were associated with both platinum response status and prognosis, which was further validated by the Fudan University Shanghai cancer center (FUSCC) cohort.

Conclusion: These findings reveal a specific risk model that could serve as effective biomarkers to identify patients' platinum response status and predict survival outcomes for OC patients. PNLDC1, SLC5A1, and SYNM are the hub genes that may serve as potential biomarkers in OC treatment.

Citing Articles

Prognosis and immune infiltration prediction in neuroblastoma based on neutrophil extracellular traps-related gene signature.

Aierken Y, Tan K, Liu T, Lv Z Sci Rep. 2025; 15(1):5343.

PMID: 39948114 PMC: 11825912. DOI: 10.1038/s41598-025-88608-x.

Hesperidin inhibits colon cancer progression by downregulating SLC5A1 to suppress EGFR phosphorylation.

Li X, Wu Z, Yuan L, Chen X, Huang H, Cheng F J Cancer. 2025; 16(3):876-887.

PMID: 39781340 PMC: 11705064. DOI: 10.7150/jca.104867.

Fan S, Xie X, Wei W, Hua T Phenomics. 2024; 4(4):379-393.

PMID: 39583315 PMC: 11584837. DOI: 10.1007/s43657-024-00163-z.

Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on drug response genes to predict prognosis and therapeutic response in ovarian cancer.

Zhang Z, Chen M, Peng X Heliyon. 2024; 10(13):e33367.

PMID: 39040239 PMC: 11260940. DOI: 10.1016/j.heliyon.2024.e33367.

Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq.

Hua T, Liu D, Zhang X, Li S, Wu J, Zhao Q Eur J Med Res. 2024; 29(1):358.

PMID: 38970067 PMC: 11225302. DOI: 10.1186/s40001-024-01948-8.

References

Chang X, Dong Y . CACNA1C is a prognostic predictor for patients with ovarian cancer. J Ovarian Res. 2021; 14(1):88. PMC: 8252246. DOI: 10.1186/s13048-021-00830-z. View

Krepischi A, Maschietto M, Ferreira E, Silva A, Costa S, da Cunha I . Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors. Mol Cytogenet. 2016; 9:20. PMC: 4765068. DOI: 10.1186/s13039-016-0227-y. View

Wang P, Wang Y, Hang B, Zou X, Mao J . A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 2016; 7(34):55343-55351. PMC: 5342421. DOI: 10.18632/oncotarget.10533. View

Ehira N, Oshiumi H, Matsumoto M, Kondo T, Asaka M, Seya T . An embryo-specific expressing TGF-β family protein, growth-differentiation factor 3 (GDF3), augments progression of B16 melanoma. J Exp Clin Cancer Res. 2010; 29:135. PMC: 2972255. DOI: 10.1186/1756-9966-29-135. View

Parrish R, Spencer 3rd H . Effect of normalization on significance testing for oligonucleotide microarrays. J Biopharm Stat. 2004; 14(3):575-89. DOI: 10.1081/BIP-200025650. View

Raman P, Maddipati R, Lim K, Tozeren A . Pancreatic cancer survival analysis defines a signature that predicts outcome. PLoS One. 2018; 13(8):e0201751. PMC: 6084949. DOI: 10.1371/journal.pone.0201751. View

Liu G, Chen L, Ren H, Liu F, Dong C, Wu A . Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma. Int J Biol Sci. 2018; 14(14):2012-2022. PMC: 6299362. DOI: 10.7150/ijbs.28249. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Wang Q, Liu X . Screening of feature genes in distinguishing different types of breast cancer using support vector machine. Onco Targets Ther. 2015; 8:2311-7. PMC: 4556031. DOI: 10.2147/OTT.S85271. View

10.

Bi J, Bi F, Pan X, Yang Q . Establishment of a novel glycolysis-related prognostic gene signature for ovarian cancer and its relationships with immune infiltration of the tumor microenvironment. J Transl Med. 2021; 19(1):382. PMC: 8425093. DOI: 10.1186/s12967-021-03057-0. View

11.

Goeman J . L1 penalized estimation in the Cox proportional hazards model. Biom J. 2009; 52(1):70-84. DOI: 10.1002/bimj.200900028. View

12.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

13.

Miao Y, Zhang H, Su B, Wang J, Quan W, Li Q . Construction and validation of an RNA-binding protein-associated prognostic model for colorectal cancer. PeerJ. 2021; 9:e11219. PMC: 8029696. DOI: 10.7717/peerj.11219. View

14.

Lai B, Xiao Y, Pu H, Cao Q, Jing H, Liu X . Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet. 2011; 285(5):1455-61. DOI: 10.1007/s00404-011-2166-5. View

15.

Granger B, Lazarides E . Synemin: a new high molecular weight protein associated with desmin and vimentin filaments in muscle. Cell. 1980; 22(3):727-38. DOI: 10.1016/0092-8674(80)90549-8. View

16.

Bonome T, Levine D, Shih J, Randonovich M, Pise-Masison C, Bogomolniy F . A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008; 68(13):5478-86. PMC: 7039050. DOI: 10.1158/0008-5472.CAN-07-6595. View

17.

Li T, Hui W, Halike H, Gao F . RNA Binding Protein-Based Model for Prognostic Prediction of Colorectal Cancer. Technol Cancer Res Treat. 2021; 20:15330338211019504. PMC: 8182183. DOI: 10.1177/15330338211019504. View

18.

Markman M, Liu P, Wilczynski S, Monk B, Copeland L, Alvarez R . Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003; 21(13):2460-5. DOI: 10.1200/JCO.2003.07.013. View

19.

Goel M, Khanna P, Kishore J . Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2011; 1(4):274-8. PMC: 3059453. DOI: 10.4103/0974-7788.76794. View

20.

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View